Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/49961
Campo DC Valoridioma
dc.contributor.authorTavío, María M.
dc.contributor.authorAquili, Virginia D.
dc.contributor.authorPoveda, José B.
dc.contributor.authorAntunes, Nuno T.
dc.contributor.authorSánchez-Céspedes, Javier
dc.contributor.authorVila, Jordi
dc.contributor.otherSanchez-Cespedes, Javier
dc.contributor.otherPoveda, Jose
dc.contributor.otherVila, Jordi
dc.date.accessioned2018-11-24T12:08:36Z-
dc.date.available2018-11-24T12:08:36Z-
dc.date.issued2010
dc.identifier.issn0305-7453
dc.identifier.urihttp://hdl.handle.net/10553/49961-
dc.description.abstractThe role of sdiA in the acquisition of low-level multidrug resistance (MDR) was analysed and compared with that of marA and soxS in two Escherichia coli clinical isolates and two in vitro-selected mutants.The mutants were developed by growth in lomefloxacin and ceftazidime. The sdiA, marA, soxS, ftsI, tolC and acrB gene transcript levels were determined by RT-PCR. Analyses of 2,4-dinitrophenol susceptibility, the effect of an active efflux inhibitor on antibiotic and mitomycin C susceptibility, beta-lactamase hydrolytic activity, outer and inner membrane proteins and acrR gene sequencing were also performed.Both mutants showed elevated marA and sdiA gene transcript levels, which were associated with increased susceptibility to 2,4-dinitrophenol; soxS overexpression was only seen in the mutant selected with ceftazidime. The two mutants showed MDR phenotypes in which ceftazidime, cefpirome and aztreonam MICs increased 4- to 128-fold, in addition to decreased susceptibility to quinolones, chloramphenicol and mitomycin C. The highest ceftazidime MIC in one of the mutants coincided with a frameshift mutation in acrR and the highest transcript level of ftsI (penicillin-binding protein 3), but not with a higher beta-lactamase activity. Likewise, active efflux associated with increased levels of acrB and tolC and decreased OmpF expression contributed to low-level MDR in both mutants.marA and sdiA overexpression was a common feature of multidrug-resistant mutants selected by growth in lomefloxacin and ceftazidime. To our knowledge, this report is the first to describe in vitro selection with a fluoroquinolone or ceftazidime triggering sdiA overexpression in E. coli isolates.
dc.publisher0305-7453
dc.relation.ispartofJournal of Antimicrobial Chemotherapy
dc.sourceJournal of Antimicrobial Chemotherapy[ISSN 0305-7453],v. 65 (dkq112), p. 1178-1186
dc.subject.otherMultiple Antibiotic-Resistance
dc.subject.otherOrganic-Solvent Tolerance
dc.subject.otherBeta-Lactam Antibiotics
dc.subject.otherEnterica Serovar Typhimurium
dc.subject.otherPenicillin-Binding Proteins
dc.subject.otherFluoroquinolone Resistance
dc.subject.otherPseudomonas-Aeruginosa
dc.subject.otherAntibacterial Activity
dc.subject.otherQuinolone Resistance
dc.subject.otherCell-Division
dc.titleQuorum-sensing regulator sdiA and marA overexpression is involved in in vitro-selected multidrug resistance of Escherichia coli
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeArticlees
dc.identifier.doi10.1093/jac/dkq112
dc.identifier.scopus77953517647
dc.identifier.isi000277734500013
dcterms.isPartOfJournal Of Antimicrobial Chemotherapy
dcterms.sourceJournal Of Antimicrobial Chemotherapy[ISSN 0305-7453],v. 65 (6), p. 1178-1186
dc.contributor.authorscopusid6701659492
dc.contributor.authorscopusid15135115800
dc.contributor.authorscopusid7005736558
dc.contributor.authorscopusid57196635499
dc.contributor.authorscopusid56628972200
dc.contributor.authorscopusid7202012753
dc.description.lastpage1186
dc.identifier.issuedkq112
dc.description.firstpage1178
dc.relation.volume65
dc.type2Artículoes
dc.identifier.wosWOS:000277734500013
dc.contributor.daisngid2590173
dc.contributor.daisngid2734488
dc.contributor.daisngid498394
dc.contributor.daisngid1398738
dc.contributor.daisngid1566728
dc.contributor.daisngid24031
dc.identifier.investigatorRIDB-1063-2014
dc.identifier.investigatorRIDL-5987-2014
dc.identifier.investigatorRIDP-3613-2016
dc.contributor.wosstandardWOS:Tavio, MM
dc.contributor.wosstandardWOS:Aquili, VD
dc.contributor.wosstandardWOS:Poveda, JB
dc.contributor.wosstandardWOS:Antunes, NT
dc.contributor.wosstandardWOS:Sanchez-Cespedes, J
dc.contributor.wosstandardWOS:Vila, J
dc.date.coverdateAbril 2010
dc.identifier.ulpgces
dc.description.jcr4,659
dc.description.jcrqQ1
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR Investigación Básica y Aplicada en Ciencias de la Salud-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.deptGIR IUSA-ONEHEALTH1: Epidemiología, Medicina Preventiva Veterinaria y Zoonosis-
crisitem.author.deptIU de Sanidad Animal y Seguridad Alimentaria-
crisitem.author.deptDepartamento de Patología Animal, Producción Animal, Bromatología y Tecnología de Los Alimentos-
crisitem.author.orcid0000-0002-1808-7461-
crisitem.author.orcid0000-0002-9846-2427-
crisitem.author.parentorgDepartamento de Ciencias Clínicas-
crisitem.author.parentorgIU de Sanidad Animal y Seguridad Alimentaria-
crisitem.author.fullNameTavío Pérez, María Del Mar-
crisitem.author.fullNamePoveda Guerrero, José Bismarck-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

38
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

38
actualizado el 17-nov-2024

Visitas

71
actualizado el 25-may-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.